StockNews.AI
NMRA
StockNews.AI
156 days

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed Against Neumora Therapeutics, Inc.

1. A class action lawsuit has been filed against Neumora Therapeutics. 2. Claims include false statements in initial public offering documents. 3. Issues relate to Phase Two Trials and patient data inadequacies. 4. Investors can seek lead plaintiff status by April 7, 2025. 5. Potential investor losses may create liability for Neumora.

5m saved
Insight
Article

FAQ

Why Bearish?

Class action lawsuits typically negatively impact stock prices, evident in past biotech cases like Lumos Pharma (LUMO) and AcelRx Pharmaceuticals (ACRX), where significant legal challenges led to price declines. The allegations against Neumora involve serious claims of misleading information regarding clinical trials that could reduce investor confidence.

How important is it?

The ongoing litigation could significantly affect investor perception and stock price, given the serious nature of the allegations and the potential financial repercussions for the company. Such lawsuits typically decrease market trust, particularly in biotech stocks reliant on favorable trial outcomes.

Why Short Term?

The lawsuit and its potential financial implications are immediate concerns for investors, particularly as the lead plaintiff deadline approaches on April 7, 2025. Similar past occasions show that stock prices can react sharply in the short-term during litigation announcements.

Related Companies

LUMOACRX
RADNOR, Pa., March 16, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora") (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora's prospectus and registration statement (collectively, the "Offering Documents") issued in connection with Neumora's initial public offering held on or around September 15, 2023. The lead plaintiff deadline is April 7, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Neumora losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/neumora-therapeutics-inc?utm_source=PR&utm_medium=link&utm_campaign=nma&mktm=r You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT:The complaint alleges that, in the Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend the original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder ("MDD") to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) Neumora also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. THE LEAD PLAINTIFF PROCESS:Neumora investors may, no later than April 7, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Neumora investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/neumora-therapeutics-inc?utm_source=PR&utm_medium=link&utm_campaign=nma&mktm=r ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com. CONTACT:Kessler Topaz Meltzer & Check, LLPJonathan Naji, Esq.(484) 270-1453280 King of Prussia RoadRadnor, PA 19087[email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP

Related News